Get started

LABU

KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over its moving averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and $75.00 for most of the position in consideration of the analyst report.
NASDAQ:KRROLong
by AwesomeAvani
1
XBI biotech ETF EW count optionsSharing an intermediate view of the EW count options for XBI. The short-term bullish range is $97-$98. The short-term bearish target ranges are $89 - $88.50 and $87. The bearish count, in red, drops the price to $81ish as first support. If, $81 range does not hold, $72 is the C wave target. In the meantime, I anticipate a lot of chop in the range from $86 - $100 in the next couple months until a rate cut occurs. As speculation of a rate cut increases, the price can begin to gravitate toward $104. When an interest rate cut is proposed, XBI will blast to the $140s but I am reserved about this outcome at this time.
AMEX:XBI
by MontBel
1
VTYX- a risky biotechnology penny stock LONGVTRX is on a 120 minute chart, currently trading at 90% off its ATH and 50% above its absolute long term support level. Price tried to cross above the long term mean VWAP 3 months ago but was rejected. I anticipate that in time it will try to so so again. From 3.3 to a target of 9 would be a move in the neighborhood of 300%. I will take a small position long trade here. This will be highly volatile. I will place a 25% stop loss to give VTRX room to roam for a couple of earnings periods. Once the price rises 25% I will convert to a trailing stop loss of 25% and make the then risk free trade low maintenance.
NASDAQ:VTYXLong
by AwesomeAvani
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and the drive for an HIV vaccine. MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and maybe falling to the trigger line. I will take a one- third partial off my position here and wait for a pullback with reversal to add back into the position at a lower price. The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management will help me keep it that way.
NASDAQ:MRNALong
by AwesomeAvani
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in an ascending channel NVAX is now at the bottom of the channel perhaps due to the general market moves this week. From here it can move up in the channel or breakdown and fall into a significant correction from the uptrend since May 10th. I am bullish on NVAX and have a prior perspective of an insider. I have realized profit six figures from my call options for January 2025 and have a large number remaining in the trade. At this juncture, I will watch for NVAX to move up in the channel and take a trade of shares and some call options for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options. The FDA is currently reviewing some COVID vaccine data which is particularly relevant to NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares. The options will have a 20% stop loss. Considering the level from which NVAX has fallen over a period of some period there is great potential in my opinion.
NASDAQ:NVAXLong
by AwesomeAvani
2
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I see a dip on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with the first upper VWAP band line and then the 135-138 zone underneath the second upper line shown in thin red on the chart. This ETF smooths out the volatility characteristic of some of the smaller biotechnology firms making it safer albeit with lesser rewards expectations. Positions in NVAX and MRNA are having a good start to the week and will reflect in a small way in this ETF which has broad constituent stocks within its portfolio.
AMEX:XBILong
by AwesomeAvani
1
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality focused and helps the customer feel good about him/her- self. It does not have any gender orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator did its thing as the post-earnings action began. I see this stock as a good long to hold into the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart horizontal resistance overhead and traders will note that. I see the bullish momentum continuing perhaps with some healthy ( no pun intended) corrections while underway. Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
NYSE:HIMSLong
by AwesomeAvani
LCTX gets upgrade and is technically setup LONGLCTX on the weekly chart here has been falling since late 2021 and found support at the bottom of the high volume area of the volume profile and ranged between it and the POC line for the past 18 months. The is a high end clinically active biotechnology firm using stem cells to produce therapeutic cell lines . ( One experiment using the mammary glands of cows imbedded with cells that make insulin to make a weak milk solution containing insulin and then concentrate it for cheap insulin is quite remarkable- ) How about some special milk for to have with your sugar buzz) see more in the here link en.wikipedia.org Anyway, price rose into triple confluence- the anchored mean VWAP, the POC line, the upper boundary of the high volume area. A new analysis targets 7. Smart money is paying attention. My smart money is paying a lot of attention. I understand the science and the market that LCTX could reach in due time. I am not an insider but close. Enough said. My target is the tweezer tops of 2022 at 2.5 and so 65-70% upside in the near to intermediate term and after that maybe the analysis will revise the target up or down I am guessing the former.
AMEX:LCTXLong
by AwesomeAvani
STRO a biotech startup flips into positive earnings LONGSTRO on a 240 minute chart got trader interest out of earnings that were projected to be net cash outflow into reported actual earnings. This is a remarkable turnaround. The RSI lines surged. The predictive algorithm which relies on a lookback of the regression line for analysis toward the future forecasts a move up much higher. I will take a long trade here seeking 50-60% in a month although the forecast is for a doubling.
NASDAQ:STROLong
by AwesomeAvani
BCAB post earnings is set up LONGBCAB a medical technology penny stock had a good beat on earnings. This means the cash burn was only 70% of what was expected. On the strength of that traders reached. The indicators suggest more upside including RSI lines crossing over the 50 level and the MACD lines bouncing up on the approach to the zero horizontal line. The supply and demand curves crossed. The Luxalgo predictive algorithm doing a pattern lookback analysis has a trend up. I will take a long trade here attempting to get a good piece of the move for realized profit.
NASDAQ:BCABLong
by AwesomeAvani
1
VINC a speculative biotech penny stock LONGVINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the rug pull. This is a high tight bull flag pattern which typically results in another leg higher of the same magnitude. I suppose that is in clean trading without any manipulation. If this takes off again it might be worth trying with a small position so long as the trader can hit a button to close the full position when the sudden reversal occurs. I will trade this long with a group of moving averages to make alerts for crossing lines and slopes levelling out and see if it can go anywhere.
NASDAQ:VINCLong
by AwesomeAvani
32
VTYX- Buy the Pullback after a massive Bullish Surge LONGVTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and went parabolic on the next day and then faded while the moving averages and VWAP lines caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX did less than a full 0.5 retracement as a sign of strength. I will take a long trade here targeting 16% upside to the top pivot of the recent price action. If the price can reach the target I will take half screening for higher-than-normal volatility. At present the volatility has mildly popped over the running mean telling me the continuation is on the ready. The plus here is earnings will report on March 24th so there is one month for traders to run the price up on this stock in that anticipation. Options are avaiable for call contracts expiring March 15th.
NASDAQ:VTYXLong
by AwesomeAvani
EPIX - Biotech Pre-earnings Run LONGEPIX on the 15-minute chart shows a solid trend up with a set of moving averages as the guardrails now in a bit of a pullback. The after-hours price action will not appear on the chart but price jumped 5%. Earnings are anticipated for 2/8 or 2/9 as best as I can tell. Internet search information is not consistent. So, if tomorrow this is still pre-earnings but price popped 5% overnight, I will take a small long position. If the price is still pulled back to the slowest moving average, I will take a larger position. No matter I will assess it on a 3-5 minute time frame and recheck internet information regarding an earnings report. One news catalyst is that Secretary of Defense has been in and out of the hospital ( DC VAMC) with prostate cancer and maybe currently getting treatment in a clinical trial of an EPIX drug per the NIH in Bethesda. Biotech is forecasted to be one of the hottest sectors for 2024. EPIX has a trend up that impresses me. I will go long on this when I find a best entry and possibly in the next trading session. The options chain is minimal volume as so represents a liquidity trap. I will not go there.
NASDAQ:EPIXLong
by AwesomeAvani
2
BLUE- a biotechnology earnings penny stock LONGBLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting support from the mean anchored VWAP. The last trading day was a quick rise with momentum in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings. My target is 1.90 about the high of the prior trend up and below the second VWAP line above the mean. A tight stop loss at 1.53 ( below the flag's consolidation) will make it more likely the trade will be a 20% winner. I have taken call options strikng $1.50 for March 15th for $20 each. or a small loss of 2-3%
NASDAQ:BLUELong
by AwesomeAvani
LEXX a penny medical stock LONGLEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of the all high highs of 19 at the neckline of a head and shoulders back in 2018-2019, In short it has a lot of upside if it can show earnings growth on higher revenues. For now targets are 4.15 the high of 2022 and 6.45 the high of 2021 marked on the chart in black horizontal lines. LEXX is a money burning medical penny it is high risk like its peers. The reward potential is as much as 7X and more realistically 2X in the intermediate term. I will so long here with the risk in mind in the context of the reward potential.
NASDAQ:LEXXLong
by AwesomeAvani
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
LABU a 3X leveraged ETF of biotechnology stocks LONGLABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged funds have time decay from the leveraging and management fees and are meant to be for short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may take 1-2 shares off the position to realize some profit and recycle ( compound) into the next buy. According to those that follow sectors, LABU should outperform this year.
AMEX:LABULong
by AwesomeAvani
2
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does have other projects in its pipeline admittedly on various timelines with varying probabilities of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology, medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer but is weak compared with most of the others I have selected especially with LLY, which is high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical are quite strong as well. United Healthcare is dominant in the insurance subsector and strong overall. One often effective strategy is to buy when an instrument is oversold and undervalued at a discount. I will buy NVAX here no matter that I have insider connections with one of those medical device companies and a few not on the list. Sentiment only goes so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a penny stock with high volumes, low cost of entry and perhaps low floats, volatility is underscored and exaggerated if a volume inflow gets underway That said, a short squeeze is within the spectrum of possibilities. Enough said for now.
NASDAQ:NVAXLong
by AwesomeAvani
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish momentum capped off with a breakout from the high volume area into a bullflag to rest the weekend. I am in this stock going and now is an opportunity to add to the position. If a trader wants to know what I consider to be targets upside, let me know. Medical technology is expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I believe it has significant upside for the long term. in the short term, earnings are expected on February 28th so this is a trade to consider on that run up. Call options for March 2 or March 16 can be considered.
NASDAQ:NVAX
by AwesomeAvani
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow remains as a challenge. The volume and volatility show both are heightened in the pre-earnings run- up. . This is a risky earnings play, NRIX does not yet make money like many other young biotechnology companies trying to grow However, because it lost less than forecasted, buyer interest has increased. There is an absence of any options volume and so illiquidity prevents consideration of options trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%) If earnings disappoint trader expectations and price fades I will stop out with a loss of about 2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology is expected to be one of the hottest subsectors of 2024. This could be one of them.
NASDAQ:NVAXLong
by AwesomeAvani
CARA a Biotech Pennys Stock with earnings coming LONGCARA is here on a 15 minute chart. The earnings report is due March 4th. The price action is already demonstrative of bullish momentum. CARA rose 60% this past week. It is still on sale at 95% off its all time high. Spiking buying volume, and so an upgoing Price Vulme Trend and squeeze release triggers on lower time frames all have CARA moving well prior to earnings. I see this as a long trade setup quite well. The available option contract on a thin-chain for strike 2.5 on March 15 added 20% on Friday. I will pass on any options contracts as the thin volume is a higher-than-acceptable risk. I will be more than happy with another 60% price rise in the upcoming week and it could be more.
NASDAQ:CARALong
by AwesomeAvani
RZLT Biotechnology Penny Stock Reports in the next day LONGRZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next day so this is a buy for me. I can see that price broke above a recent supply/resistance zone. This penny stock likely cannot be shorted so there is no selling pressure to be exerted until present longs have found their target. This can add to the momentum without the drag of that short selling. A penny here and a penny there it all adds up over time especially with compounding in active trading with penny stocks that have great range.
NASDAQ:RZLTLong
by AwesomeAvani
2